Launch of ResMed’s AirCurve 10 CS PaceWave™ Reinvents the Management of Central Sleep Apnoea and Could Play a Pivotal Role in the Care of Millions of Patients with Concurrent Chronic Heart Failure

ResMed, a pioneer and global leader in sleep and respiratory medicine, has announced the launch of its ResMed Air Solutions range, led by the intelligent, cloud-enabled  AirCurve 10 CS PaceWave™ with AirView  system. This is the first device to combine remote monitoring with ResMed’s innovative PaceWave™ Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy. Through a unique patented algorithm, PaceWave^TM MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing. This is especially relevant for those suffering from Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly seen in patients with heart failure.^1,2,3 CSA/CSR is thought to affect up to 50%^4,5,6 of patients with chronic heart failure and has been linked to increased mortality and morbidity in this patient population.⁷ The use of PaceWave^TM MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF, the world’s largest randomised trial in this field.

Commenting on the launch of ResMed’s Air Solutions, Anne Reiser, President of ResMed Europe and Asia Pacific, said: “The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave ^TM  with AirView  represents a landmark shift in the treatment of central sleep apnoea. By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services.

“This launch may also have significant implications for many patients with chronic heart failure. The findings of the SERVE-HF study will indicate the scale of benefit PaceWave^TM MV-ASV may bring but there is real potential for a step-change on how we prioritise breathing management in this patient population.”

ResMed’s AirCurve 10 CS PaceWave™ is now available in select European countries.

About the SERVE-HF study

It is thought that around 14 million people in Europe are currently living with heart failure⁸ and that 30-50% are at risk of having concurrent central sleep-disordered breathing.^4,5,6 SERVE-HF is the world’s largest randomised study to investigate if treating chronic heart failure patients who also have CSA with PaceWave^TM MV-ASV therapy may improve outcomes including mortality and morbidity. More than 1,325 patients have taken part in the study, which completed enrolment in 2013. More details on SERVE-HF can be found at www.servehf.com.

About ResMed

The global team at ResMed (NYSE:RMD) are united in their commitment to changing lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other key chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.

# ENDS #

¹ Oldenburg O et al. Adaptive servoventilation improves cardiac function and respiratory stability. Clin Res Cardiol2011;100(2):107–15.

² Allam JS et al. Efficacy of adaptive servo-ventilation in treatment of complex and central sleep apnea syndromes.Chest 2007;132(6):1839–46.

³ Morgenthaler TI et al. Adaptive servo-ventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007;30(4):468–75.

⁴ Akiko Noda et al. Therapeutic Strategies for Sleep Apnea in Hypertension and Heart Failure. Pulmonary Medicine. 2013 Article ID 814169.

⁵ Olaf Oldenburg et al., Sleep-disordered breathing in patients with symptomatic heart failure, Eur J Heart Fail. 2006 doi:10.1016/j.ejheart.2006.08.003.

⁶ Paulino et al. Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. Archives of Cardiovascular Disease. 2009; 102: 169-175.

⁷ Cowie et al. Sleep-Disordered Breathing in Heart Failure – Current State of the Art. Cardiac Failure Review (2015) Vol. 1 Issue 1.

⁸ Remme WJ et al. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J. 2005; 26: 2413–2421.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Reynolds-MacKenzie
Tim Cockroft
+44 207 861 2805
+44 7957 325 583
tim@reynoldsmackenzie.com
or
ResMed
Odile Bigaignon
Cardiology Director, Europe
+33 426 100 245
+33 6 26 38 55 58
Odile.Bigaignon@resmed.com